The clinical stage biopharmaceutical company Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) has seen its stock go through a fairly rough time in recent weeks. Over the course of the past month, the stock has tanked by as much as 16% owing to a steady selloff.
Trading Data
On Monday, MTNB stock moved up 1.30% to $0.8864 with 649k shares, compared to its average volume of 1.22 million shares. The stock has moved within a range of $0.8600 – 0.8924 after opening trade at $0.86.
Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022
However, such a fall can also be an opportunity for enterprising investors and hence, it may be time to figure out if it is so in case of Matinas. Yesterday, the company was actually in the news after it announced that it was going to host a live video webcast for a conference call next week on January 25, 2022.
The conference call in question is going to begin at 8-30 a.m. Eastern Time. In that conference call, Matinas is going to provide an overview of its business outlook for the year 2022 and in addition to that it is also going to send out a corporate update. However, that is not all.
Over the course of the conference call, the senior management of the company is also going to be in attendance and will provide detailed updates with regards to the projects that are currently ongoing. It may be a good time to keep an eye on the Matinas stock.
Technical Data
MTNB stock is trading below the 20-Day and 50-Day Moving averages of $0.96 and $1.02 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.93.
